key: cord-0939455-5keqt37l
authors: Xiong, Xiaoming; Jiao, Xiaofei; Li, Huayi; Zeng, Shaoqing; Wang, Ya; Gao, Qinglei
title: Glucocorticoid benefits the ventilatory function of sever/critical COVID-19 patients
date: 2020-11-18
journal: J Infect
DOI: 10.1016/j.jinf.2020.11.017
sha: c1ae09b5b4bcf3b9f86f02623b3eb7fe1c472210
doc_id: 939455
cord_uid: 5keqt37l

nan

The coronavirus disease 2019 has become a global pandemic 1 . With our accumulating experience of combatting COVID-19, many medications were repurposed to counteract it 2 . Cytokine storm and immune disorders are reportedly major mediators in acute respiratory distress syndrome and multiple organ failure, leading to poor prognosis of COVID-19 3 . Therefore, glucocorticoid (GC), an affordable, nonspecific anti-inflammatory and immunoregulatory drug, has been suggested to treat patients with COVID-19, especially those with critical diseases.

Though GC has been used in more and more COVID-19 patients, the benefit of GC is still controversial. Because of the immunosuppressive function of GC, it is inclined to delay viral clearance 4 , cause secondary infections, lead to physiological deterioration 5 , and relate to higher mortality, longer length of hospitalization 6 . However, the effects of GC on the ventilatory function of COVID-19 patients were incompatible 7, 8 .

This study aims to investigate how GC affects the duration of oxygen supply for (21.9%) cases received GC treatment and 621 (78.1%) cases did not. In the severe/critical group, 254 (39%) cases received GC treatment and 398 (61%) cases did not. The proportion of patients receiving GC therapy was prominently higher in the severe/critical group (Table 2) . Some laboratory tests, also known as severity indicators, showed the situation of GC group was more serious than that of non-GC group in both general and severe/critical patients. Consequently, the hospitalization time and oxygen supply duration of GC group were longer than those of non-GC group in general patients. However, among severe/critical COVID-19 patients, we did not observe longer oxygen supply duration in GC group ( This multicenter study showed COVID-19 patients with GC therapy were more serious at admission. However, there was no significant difference in oxygen supply duration between GC group and non-GC group among severe/critical patients, as well as patients with an initial CRP ≥ 20 mg/L, indicating these patients might benefit more from GC therapy.

There are some limitations in our study. First, we did not consider the types of ventilation and only calculated the total duration of oxygen supply. Second, the patients involved in our study were mainly from hospitals in Wuhan, which might cause some bias to this study. Finally, the dosage of GC use for patients was ignored, and we just considered whether patients used GC or not.

In summary, we did not observe shorter oxygen supply duration of severe/critical COVID-19 patients with GC treatment, but we have faith in the benefit of GC on the ventilatory function of these patients.

We thank Yue Gao (Tongji hospital) for revising the manuscript.

QLG, XMX and XFJ conceived this project. XMX, XFJ, HYL, SQZ, and YW collected the data. XMX and XFJ analyzed the data. XMX wrote the primitive manuscript. XFJ, HYL and QLG reviewed and polished the manuscript. All authors read and approved the final manuscript for publication.

The authors declared that there are no conflicts of interest.

Not applicable.

All authors reviewed the manuscript and approved the publication.

The datasets used and/or analyzed in this study are available from the corresponding author on reasonable request.

The study design was approved by ethics committees of Tongji hospital (TJ-IRB20200406), and the requirement for informed consent was waived by the ethics committees. The trial has been registered in Chinese Clinical Trial Registry 

GC: glucocorticoid IQR: interquartile range CHD: coronary heart disease COPD: chronic obstructive pulmonary disease CKD: chronic kidney disease CRP: C-reactive protein IL-6: interleukin-6 IL-8: interleukin-8 IL-1β: Interleukin-1 beta TNFα: tumor necrosis factor α WBC: white blood cell Table 2 . Analysis of glucocorticoid on oxygen supply duration of COVID-19 patients with different severity.

General group (N=795) Severe and critical group (N=652) # :1379 patients (583 patients with non-GC use and 171 patients with GC use in general group and 377 patients with non-GC use and 248 patients with GC use in severe and critical group) with CRP test results at admission were included in this analysis. 

inflammatory response, median (IQR) CRP # , (mg/L)

and 398 patients with non-GC use and 254 patients with GC use in severe and critical group) with lymphocyte test results at admission were included in this analysis. Ϫ : 1443 patients (620 patients with non-GC use and 174 patients with GC use in general group and 397 patients with non-GC use and 252 patients with GC use in severe and critical group) with lymphocyte test results at admission were included in this analysis.

GC: glucocorticoid IQR: interquartile range CRP: C-reactive protein IL-6: interleukin-6 IL-8: interleukin-8 TNFα: tumor necrosis factor α WBC: white blood cell